Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2007

01-10-2007

Glycemia, triglycerides and disease severity are best associated with higher platelet activity in patients with stable coronary artery disease

Authors: Pavel P. Osmancik, Frantisek Bednar, Heidi Móciková

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2007

Login to get access

Abstract

Background

Inconsistent findings are reported about the relation of platelet activity to disease severity in stable patients with chronic coronary artery disease (CAD). Nevertheless, most reports studied only very small groups of patients. The purpose aim of our study was to assess the relation of platelet activity to disease severity in sufficient number of patients with chronic CAD.

Methods

One hundred and sixty stable patients with chronic CAD were studied (25 with single-, 63 with double- and 72 with triple-vessel disease). 91% of them were on aspirin, 1.6% on clopidogrel medication. Platelet activity was determined as membrane expression of antigens CD62P (P-selectin, as % of positive cells) and CD41 (part of GpIIb/IIIa integrin, as mean fluorescence intensity) by flow cytometry. Platelet aggregability was measured by ADP-optical aggregometry. Data sets were compared by Kruskal-Wallis test, correlation by Spearman test. Data are shown as median with 25–75 percentiles.

Results

Membrane CD62P expression correlated with vessel severity (P < 0.001, Kruskal-Wallis test). Patients with triple-vessel disease had the highest CD62P expression (1.6; 1.1–2.0) followed by patients with double-vessel (1.2; 0.63–1.95) and single-vessel (0.7; 0.30–0.84) disease. Positive correlation was found between CD62P expression with triglycerides (r = 0.49, P < 0.05) and CD41 with fasting glucose (r = 0.48, P < 0.05). No differences in CD41 expression or ADP aggregability were found between groups.

Conclusion

Higher platelet activity is present in patients with more severe CAD. More aggressive anti-platelet treatment in these patients should be considered, especially when metabolic syndrome is simultaneously present.
Literature
1.
go back to reference Huo Y, Ley KF (2004) Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 14:18–22PubMedCrossRef Huo Y, Ley KF (2004) Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 14:18–22PubMedCrossRef
2.
go back to reference Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD (2005) Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets 16:368–371PubMedCrossRef Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD (2005) Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets 16:368–371PubMedCrossRef
3.
go back to reference Ekmekci H, Isler I, Sonmez H et al (2006) Comparison of platelet fibronectin, ADP-induced platelet aggregation and serum total nitric oxide (NOx) levels in angiographically determined coronary artery disease. Thromb Res 117:249–254PubMedCrossRef Ekmekci H, Isler I, Sonmez H et al (2006) Comparison of platelet fibronectin, ADP-induced platelet aggregation and serum total nitric oxide (NOx) levels in angiographically determined coronary artery disease. Thromb Res 117:249–254PubMedCrossRef
4.
go back to reference Gawaz M, Neumann FJ, Schomig A (1999) Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 99:E1–E11PubMed Gawaz M, Neumann FJ, Schomig A (1999) Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 99:E1–E11PubMed
5.
go back to reference Michelson AD (2004) Platelet function testing in cardiovascular diseases. Circulation 110:e489–e493PubMedCrossRef Michelson AD (2004) Platelet function testing in cardiovascular diseases. Circulation 110:e489–e493PubMedCrossRef
6.
go back to reference Williams MS, Kickler TS, Vaidya D, Ng’alla LS, Bush DE (2006) Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis 21:241–247PubMedCrossRef Williams MS, Kickler TS, Vaidya D, Ng’alla LS, Bush DE (2006) Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis 21:241–247PubMedCrossRef
7.
go back to reference Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N (2006) High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 133:315–322PubMedCrossRef Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N (2006) High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 133:315–322PubMedCrossRef
8.
go back to reference Lim HS, Blann AD, Lip GY (2004) Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109:2524–2528PubMedCrossRef Lim HS, Blann AD, Lip GY (2004) Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109:2524–2528PubMedCrossRef
9.
go back to reference Bhatt DL, Fox KA, Hacke W et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717PubMedCrossRef Bhatt DL, Fox KA, Hacke W et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706–1717PubMedCrossRef
Metadata
Title
Glycemia, triglycerides and disease severity are best associated with higher platelet activity in patients with stable coronary artery disease
Authors
Pavel P. Osmancik
Frantisek Bednar
Heidi Móciková
Publication date
01-10-2007
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2007
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-006-9038-z

Other articles of this Issue 2/2007

Journal of Thrombosis and Thrombolysis 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine